YH003

DRUG5 trials

Sponsors

Eucure (Beijing) Biopharma Co., Ltd

Conditions

Advanced Solid TumorsMelanomaMucosal MelanomaPancreatic Ductal AdenocarcinomaSolid Tumor

Phase 1

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

CompletedNCT04481009

Eucure (Beijing) Biopharma Co., LtdAdvanced Solid Tumors

Start: 2020-08-04End: 2022-05-26Updated: 2022-12-12

A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors

CompletedNCT05017623

Eucure (Beijing) Biopharma Co., LtdAdvanced Solid Tumors

Start: 2021-08-26End: 2023-03-02Updated: 2023-11-18

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors

CompletedNCT05176509

Eucure (Beijing) Biopharma Co., LtdSolid Tumor

Start: 2022-04-05End: 2023-08-25Updated: 2025-01-06

Phase 2

A Study to Assess YH003 in Combination with Toripalimab(anti-PD-1 MAb) Injection in Patients with Cancers

CompletedNCT05031494

Eucure (Beijing) Biopharma Co., LtdMelanoma, Pancreatic Ductal Adenocarcinoma

Start: 2021-12-08End: 2023-08-16Updated: 2025-01-06

A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma

CompletedNCT05420324

Eucure (Beijing) Biopharma Co., LtdMucosal Melanoma

Start: 2022-06-13End: 2024-03-04Updated: 2025-01-06

Related Papers

A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2024-06-011 citations

A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.

Journal of Clinical Oncology2024-06-01

A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

Journal of Clinical Oncology2022-06-012 citations

Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-204 citations

A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

Journal of Clinical Oncology2021-05-202 citations